Table 5.

Logistic regression analysis of the association between histological remission and endoscopic normalisation at Week 12 in LUCENT-1 and dependent variables of corticosteroid-free remission and clinical remission at Week 40 in LUCENT-2 in mirikizumab induction responders who were re-randomised to mirikizumab 200 mg SC in LUCENT-2

Variable	Corticosteroid-free remission at Week 40 of LUCENT-2		Clinical remission at Week 40 of LUCENT-2
	OR [95% CI]	p-value	OR [95% CI]	p-value
Histological remission at Week 12	1.38 [0.86-2.22]	0.1908	1.37 [0.85-2.23]	0.1986
Endoscopic normalisation at Week 12	2.18 [1.03-4.93]	0.0517	2.82 [1.25-7.10]	0.0193

CI, confidence interval; OR, odds ratio; SC, subcutaneous.